Urogen, UGN-102 stage 3 stage, 18-month response time for a recurrent low-level intermediate-risk research treatment (Dor) 80.6%, 80.6%

Your email address will not be published. Required fields are marked *

Name  *

Email  *

Website

Add Comment *

Save my name, email and website in this browser for the next time I comment.

Post Comment